|
|
| References |
|
Publications |
 |
Tilson H, Doi PA, Covington DL, Parker A,Shields K, White A. The
Antiretrovirals in Pregnancy Registry A Fifteenth Anniversary
Celebration. Obstetrical & Gynecological Survey. 2007; 62
(2): 137-148. |
|
|
Watts DH, Covington DL, Beckerman
K, Garcia P, Scheuerle A, Dominguez K, Ross B, Sacks S, Chavers S,
Tilson H. Assessing the risk of birth defects associated with
antiretroviral exposure during pregnancy. American Journal of
Obstetrics and Gynecology 2004;191:985-992. |
|
|
Covington DL, Tilson H, Elder J, Doi PA, APR Steering Committee.
Assessing teratogenicity of antiretroviral drugs: Monitoring and
analysis plan of the Antiretroviral Pregnancy Registry.
Pharmacoepidemiology and Drug Safety 2004;13:537-545. |
|
|
Scheuerle A, Covington DL. Clinical Review Procedures for the
Antiretroviral Pregnancy Registry. Pharmacoepidemiology and Drug
Safety 2004;13:529-536. |
|
|
Scheuerle A, Tilson H. Birth defect classification by organ
system: A novel approach to heighten teratogenic signalling in a
pregnancy registry. Pharmacoepidemiology and Drug Safety
2002;11:465-475. |
|
|
White A, Eldridge R, Andrews E. Birth outcomes following
zidovudine exposure in pregnant women: the Antiretroviral
Pregnancy Registry. Acta Paediatrica Supplement 1997;421:86-8. |
|
|
White A, Andrews E, Eldridge R, Dickerson M, Tilson H, Elkins M,
Dai W, Hurn B, Alexander ER, Fox H, Garcia P, Rogers A. Birth
outcomes following zidovudine therapy in pregnant women. MMWR 1994
Jun 10;43(22):409, 415-416.
|
|
Published Abstracts |
|
|
Tilson H, Watts DH, Covington DL. Effective Use of
Supplemental Data in a Pregnancy Exposure Registry.
Pharmacoepidemiology and Drug Safety 2006; 15 (Supplement 1): S84.
(click to download the abstract) |
|
|
Beckerman K, Covington DL, Watts H, Tilson H, APR Steering
Committee. Risk of Birth Defects Associated with Antiretroviral
Exposure During Pregnancy. American Journal of Obstetrics and
Gynecology 2004;189 (Supplement):S56. (click
to download the abstract) |
|
|
Tilson H, Doi PA, Parker A, White A. The Antiretroviral Pregnancy
Registry: Ten Years of Progress. Pharmacoepidemiology and Drug
Safety 2003;12 (Supplement 1):S135. (click
to download the abstract) |
|
|
Covington DL, Doi PA, Tilson H, APR Steering Committee.
Antiretroviral Pregnancy Registry conforms with FDA Guidelines for
Pregnancy Exposure Registries. Pharmacoepidemiology and Drug Safety
2003;12 (Supplement 1):S22. (click
to download the abstract) |
|
|
Covington DL, Tilson H, Elder J, Doi PA, APR Steering Committee.
Assessing teratogenicity of antiretroviral drugs: Monitoring and
analysis plan of the Antiretroviral Pregnancy Registry.
Pharmacoepidemiology and Drug Safety 2002;11 (Supplement 1):S137. |
|
Presentations |
|
|
Beckerman K, Watts H, Covington D, Ross B, Tilson H, Seekins D,
Piliero P. Assessing the Risk of Birth Defects and Other Poor
Pregnancy Outcomes Associated with Antiretroviral Exposure during
Pregnancy. Poster presentation at the 16th International AIDS
Conference, Toronto, Canada, August 2006. (click to download the
presentation) |
|
|
Tilson H, Watts DH, Covington D. Effective Use of Supplemental Data
in Pregnancy Exposure Registries. Poster presentation
at the 22nd International Conference on Pharmacoepidemiology &
Therapeutic Risk Management, Lisbon, Portugal, August 2006. (click
to download presentation) |
|
|
Ross B, Beckerman K, Doi P, Covington D, Tilson H. The
Antiretroviral Pregnancy Registry: Fifteen Years of Progress and
Fifteen
Years of Data. Accepted for poster presentation at the 54th Annual
Clinical Meeting of the American College of Obstetricians &
Gynecologists, Washington, DC, May, 2006. (click to download the
presentation) |
|
|
Beckerman K, Watts H, Covington DL, Ross B, Scheuerle A, Seekins D,
Clax P, Martinez-Tristani M, Tilson H. Assessing the Risk of Central
Nervous Birth Defects Associated with Antiretroviral Exposure During
Pregnancy. Poster presentation at the 13th Annual Conference on
Retroviruses & Opportunities Infections, Denver, CO, February, 2006.
(click to download presentation) |
|
|
Scheuerle A, Watts H, Covington DL, Beckerman K, Ross B, Seekins D,
Tilson H. Assessing a Potential Signal in the Antiretroviral
Pregnancy Registry. Poster presentation at the National Birth
Defects Prevention Network Annual Meeting, Arlington, VA, January,
2006. (click to download presentation) |
|
|
Covington DL, Dominguez K, Kucik J, Watts H, Beckerman K, Ross B,
Clax P, Tilson H. Risk of Birth Defects Associated with
Antiretroviral Exposure During Pregnancy (oral presentation).
Treatment & Management of HIV Infection in United States Conference,
Atlanta, GA, September 15-18, 2005. (click to download presentation) |
|
|
Beckerman K, Covington DL, Watts H, Tilson H, APR Steering
Committee. Risk of Birth Defects Associated with Antiretroviral
Exposure During Pregnancy. Oral presentation at the 24th Annual
Society for Maternal-Fetal Medicine Scientific Meeting, New Orleans,
LA, February 2-7, 2004. (click to download presentation) |
|
|
Beckerman K, Covington DL, Garcia P, Watts H, Ross B, Chavers S,
Sacks S, Tilson H. Association between Antiretroviral Therapy during
Pregnancy and Prematurity/Low Birth Weight. Oral presentation at the
11th Conference on Retroviruses and Opportunistic Infections, San
Francisco, CA, February 8-11, 2004. (click to download
the abstract) |
|
|
Tilson H, Doi PA, Parker A, White A. The Antiretroviral Pregnancy
Registry: Ten Years of Progress. Oral presentation at the 19th
International Conference on PharmacoEpidemiology, Philadelphia, PA,
August 2003. (click
to download abstract) |
|
|
Covington DL, Tilson H, Elder J, Doi PA, APR Steering Committee.
Assessing teratogenicity of antiretroviral drugs: Monitoring and
analysis plan of the Antiretroviral Pregnancy Registry. Poster
presentation at the 18th International Conference on
PharmacoEpidemiology, Edinburgh, Scotland, August 2002. (click
to download presentation) |
|
|
Garcia PM, Covington DL, Watts DH, Beckerman K, Fox HE, Parker A,
White A. Antiretroviral therapy in pregnancy: Exposure patterns over
time and the prevalence of birth defects. Poster presentation at the
XIV International AIDS Conference, Barcelona, Spain, July 2002. (click
to download presentation) |
|
|
Garcia PM, Beckerman K, Watts DH, Fox HE, Rodriguez E, Tilson H,
Elder J. Assessing the teratogenic potential of antiretroviral
drugs: Data from the Antiretroviral Pregnancy Registry (APR). Poster
presentation at the Annual Interscience Conference on Antimicrobial
Agents and Chemotherapy, Chicago, IL, December 2001. (click
to download abstract) |
|
|
Garcia PM, Watts DH, Fox HE, Rodriguez E, Yuen N, Schwamlein C, Doi
P. Assessing the teratogenic potential of antiretroviral drugs: Data
from the Antiretroviral Pregnancy Registry (APR). Poster
presentation at the Society of Maternal and Fetal Medicine, January
2001. (click to
download abstract) |
|
|
Garcia P, Watts DH, Fox HE, Samelson R, Rodriguez E, Schwamlein C,
Elder J. Assessing the teratogenic potential of antiretroviral
drugs: Data from the Antiretroviral Pregnancy Registry (APR). Poster
presentation at the 7th Conference on Retroviruses and Opportunistic
Infections, January 2000. (click
to download presentation) |
|
Other Publications and Presentations |
|
|
Olmscheid B, and Zhang S. Use of Tenofovir Disoproxil Fumarate (TDF)
in Pregnancy: Findings from the Antiretroviral Pregnancy Registry
(APR). A poster presentation at the 48th Interscience Conference on
Antimicrobial Agents and Chemotherapy, Washington, DC, October 2008. (click
to download) |
|
|
Covington DL, Conner SD, Doi PA, Swinson J, Daniels EM. Risk of
birth defects associated with nelfinavir exposure during pregnancy.
Obstetrics and Gynecology 2004;103:1181-9. (click
to download) |
|
|
Covington DL, Doi PA, Baylor M, Tilson H. The new generation
pregnancy exposure registries. A poster presentation at the 20th
International Conference on PharmacoEpidemiology, Bordeaux, France,
August 2004. Pharmacoepidemiology and drug safety 2004; 13
(Supplement 1) S43-44. (click
to download) |
|
|
Covington DL. Multi-product / multi-company models – The
Antiretroviral Pregnancy Registry Experience. Oral presentation at
the DIA Workshop, Pregnancy Exposure Registries: Evaluating the
Teratogenic Potential of Pharmaceutical Products used at Clinical
Doses, Washington, DC, May 24-25, 2004. |
|
|
Conner SD, Covington DL, Doi PA, Swinson J, Daniels EM. Risk of
birth defects associated with nelfinavir exposure during pregnancy.
Poster presentation at the 10th Conference on Retroviruses and
Opportunistic Infections, Boston, MA, February 2003. (click
to download) |
|
|
Doi PA. Pregnancy Registries – Where Have We Been and Where are We
Going? Then and Now. Oral presentation at the 3nd Annual CBI Patient
Registries Conference, Philadelphia, PA, September 2003. |
|
|
Doi PA. Pregnancy Registries – Where Have We Been and Where are We
Going? Then and Now. Oral presentation at the 2nd Annual CBI Patient
Registries Conference, Orlando, Florida, January 2002. |
|
|
Schwamlein C. Antiretroviral Pregnancy Registry – Example of a
Long-Standing Registry. Oral presentation at the 2nd Annual CBI
Patient Registries Conference, Orlando, Florida, January 2002. |
|
|
Covington DL, Doi PA. Pregnancy exposure registries: Successes and
challenges. Oral presentation at the 39th Annual Meeting of the Drug
Information Association, San Antonio, TX, June 2003. |
|
|
Shields KE, Wiholm BE, Hostelley LS, Striano LF, Arena SR, Sharrar
RG. Monitoring outcomes of pregnancy following drug exposure: a
company-based pregnancy registry program. Drug Safety 2004;
27(6):353-67. |
|
|
McGhee K, Shields K, Benson J, Beninger P, Sharrar R. Five-year
review of maternal – fetal outcomes in patients exposed to indinavir
sulfate during pregnancy. Poster presentation at the 9th Conference
on Retroviruses and Opportunistic Infections, Seattle, WA, February
2002. |
|
|
Response from Antiretroviral Pregnancy Registry: Draft FDA Guidance
for Industry on Establishing Pregnancy Registries. Docket Number:
99D-1541. Selected APR Sponsors, written by Doi PA, December 1999. |
|
Other Registry-Related References |
|
|
Follow-Up Data Should Be Component Of Pregnancy Registry Design –
Cmte.; The Pink Sheet, vol.62, no 14, 13-14, April 3, 2000 |
|
|
Centralized Pregnancy Registries May Benefit Small Firms Most – FDA;
The Pink Sheet, vol.62, no 55, 27, April 10, 2000. |
|
|
Pregnant with fears, Drug registries help women stay informed; Rubin
R, USA TODAY, March 21, 2000; pg 01. |
|
|
Weis S, et.al. Pharmacist’s Guide to Pregnancy Registry Study. APhA,
Vol. 39, No. 6, 830-4. November/December 1999. |
|
